Price 1981.

Methods	Four randomised, double‐blind, placebo‐controlled clinical trials in the prevention and treatment of motion sickness
Participants	161 healthy men and women with a history of motion sickness. Participants ages ranged from 16 to 55 years.
Interventions	Transdermal scopolamine (0.5 mg) delivered constantly over 72 hours), placebo or oral dimenhydrinate taken either before or during a 7 to 8‐hour cruise
Outcomes	Subjective reporting of symptoms every 1 or 2 hours during exposure to motion (scale of 0 to 6) and occurrence of dry mouth, drowsiness and blurred vision
Notes	Subjects who requested extra medication received supplemental medication of 200 mcg of intramuscular scopolamine hydrobromide Schulz rating: randomisation B; allocation concealment B; selection bias B; blinding A
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear